Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.

A post-hoc analysis showed a trend towards longer PFS with XVd in patients who received limited bortezomib induction prior to ASCT treatment (Table 1 ).

also in 53,322 other papers

Median progression-free survival (PFS) was longer on XVd versus Vd in patients with 1 prior line ( P = 0.0148) or 2–3 prior lines ( P = 0.0295), lenalidomide-naïve ( P = 0.0150) or lenalidomide-treated ( P = 0.0177) patients, and PI-naïve patients ( P = 0.0003), with a strong trend in PI-treated patients.

also in 5,725 other papers